HU has an acceptable short-term toxicity profile in most patients and is currently used as the first-line of chemotherapy in hematological malignancies such as myeloproliferative neoplasm (MPN) characterized by a mutation in Janus kinase 2 (JAK2), calreticulin (CALR), and myeloproliferative leukemia virus oncogene (MPL) genes [8–11]. Here, JAK2 is linked to myeloproliferative disorder.